Madrigal posts FY 2025 net revenues of USD 958.4 million

Reuters20:04
Madrigal posts FY 2025 net revenues of USD 958.4 million

Madrigal Pharmaceuticals reported Q4 2025 product revenue, net of USD 321.08 million and FY 2025 product revenue, net of USD 958.4 million, driven by Rezdiffra (resmetirom). The company posted a Q4 2025 net loss of USD 58.58 million and an FY 2025 net loss of USD 288.28 million. Total operating expenses were USD 380.69 million in Q4 2025 and USD 1.26 billion in FY 2025, including cost of sales of USD 24.45 million (Q4) and USD 56.15 million (FY), R&D expense of USD 116.27 million (Q4) and USD 388.53 million (FY), and SG&A expense of USD 239.98 million (Q4) and USD 813.83 million (FY). Madrigal ended 2025 with cash, cash equivalents, restricted cash and marketable securities of USD 988.65 million. Operationally, Madrigal said more than 36,250 patients were on Rezdiffra as of year-end 2025, and highlighted expansion of its MASH pipeline to more than 10 programs. Recent updates included licensing global rights to six pre-clinical siRNA programs (with IND-enabling activities for initial candidates to begin in 2026) and an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, with plans to run a drug-drug interaction study with Rezdiffra and consult the FDA on a Phase 2 combination trial design in 2026. The company also noted an Orange Book-listed Rezdiffra patent providing protection into 2045, the licensing of an oral GLP-1 candidate (MGL-2086) expected to enter the clinic in Q2 2026, and the launch of Rezdiffra in Germany in September 2025 following European Commission conditional marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602190700PRIMZONEFULLFEED9657246) on February 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment